ML25318A056
| ML25318A056 | |
| Person / Time | |
|---|---|
| Site: | SHINE Medical Technologies |
| Issue date: | 12/04/2025 |
| From: | Michael Balazik NRC/NRR/DANU/UNPL |
| To: | Piefer G SHINE Technologies |
| Balazik M | |
| References | |
| EPID ML25343A486 | |
| Download: ML25318A056 (0) | |
Text
Dr. Gregory Piefer Chief Executive Officer SHINE Technologies, LLC 3400 Innovation Court Janesville, WI 53546
SUBJECT:
SHINE TECHNOLOGIES, LLC - ISSUANCE OF ORDER AND AMENDMENT NO. 5 TO CONSTRUCTION PERMIT NO. CPMIF-001, FOR THE SHINE MEDICAL ISOTOPE PRODUCTION FACILITY TO EXTEND THE LATEST DATE FOR COMPLETION OF CONSTRUCTION (EPID NO. L-2025-LLA-0133)
Dear Dr. Piefer:
The U.S. Nuclear Regulatory Commission (NRC) has issued the enclosed order to SHINE Technologies, LLC (SHINE) for the SHINE Medical Isotope Production Facility (SHINE facility).
The order amends License Condition 3.A of the SHINE facilitys construction permit in response to SHINEs license amendment request dated August 14, 2025 (Agencywide Documents Access and Management System Accession No. ML25226A150). Specifically, the order extends the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029.
The SHINE facilitys amended construction permit, amendment No. 5 to Construction Permit No. CPMIF-001, and the related NRC staff safety evaluation are also enclosed. The environmental assessment and finding of no significant impact for the extension of the latest date for completion of construction was published in the Federal Register (FR) on November 28, 2025 (90 FR 54766).
The enclosed order has been forwarded to the Office of the Federal Register for publication.
December 4, 2025
G. Piefer 2
If you have any questions, please contact me at (301) 415-2856, or via email to Michael.Balazik@nrc.gov.
Sincerely, Michael Balazik, Project Manager Non-Power Production and Utilization Facility Licensing Branch Division of Advanced Reactors and Non-Power Production and Utilization Facilities Office of Nuclear Reactor Regulation Docket No. 50-608 Construction Permit No. CPMIF-001
Enclosures:
- 1. Order
- 2. Amendment No. 5 to Construction Permit No. CPMIF-001
- 3. Safety Evaluation cc w/enclosures: GovDelivery Subscribers Signed by Balazik, Michael on 12/04/25
ML25318A056 NRR-058 OFFICE NRR/DANU/UNPL/PM NRR/DANU/UNPL/LA OGC/NLO NRR/DANU/UNPL/BC NAME MBalazik NParker JWachutka JRady DATE 11/19/2025 11/20/2025 11/20/2025 12/4/2024 OFFICE NRR/DANU/D NRR/DANU/UNPL/PM NAME JGreives MBalazik DATE 12/4/2025 12/4/2025 UNITED STATES OF AMERICA NUCLEAR REGULATORY COMMISSION In the Matter of
)
)
SHINE Technologies, LLC
)
Docket No. 50-608
)
Construction Permit No. CPMIF-001 (SHINE Medical Isotope Production Facility)
)
ORDER I.
SHINE Technologies, LLC (SHINE, licensee, permit holder) is the holder of Construction Permit (CP) No. CPMIF-001, which the U.S. Nuclear Regulatory Commission (NRC, the Commission) issued on February 29, 2016 (Agencywide Documents Access and Management System (ADAMS) Package Accession No. ML16041A473), as amended on November 30, 2022 (ML22292A319), for the construction of the SHINE Medical Isotope Production Facility (SHINE facility) in Rock County, Wisconsin. CP No. CPMIF-001 includes December 31, 2025, as the latest date for completion of the construction of the SHINE facility and expires on the latest date of completion. The SHINE facility is currently under construction.
By letter dated August 14, 2025 (M25226A150), SHINE submitted to the NRC a license amendment request in accordance with section 50.90, Application for amendment of license, construction permit, or early site permit, of title 10 of the Code of Federal Regulations (10 CFR) and 10 CFR 50.55(b). The license amendment request seeks to extend the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029.
II.
Upon review of the license amendment request, the NRC staff determined that SHINE had shown good cause for extending the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029. The staff also determined that the license amendment request involves no significant hazards consideration. The staff prepared an environmental assessment and finding of no significant impact for the requested extension of the latest date for completion of construction and published it in the Federal Register on November 28, 2025 (90 FR 54766). On the basis of the environmental assessment, the staff concluded that the requested extension will not have a significant effect on the quality of the human environment. The findings set forth above are supported by an NRC staff safety evaluation dated December 4, 2025, which is available at ML25318A056.
III.
Within 60 days after the date of publication of this notice, any persons (petitioner) whose interest may be affected by this action may file a request for a hearing and petition for leave to intervene (petition) with respect to the action. The scope of this order extending the latest date for completion of construction and any proceeding hereunder is limited to direct challenges to the CP holders asserted reasons that show good cause for the extension. Petitions shall be filed in accordance with the Commissions Agency Rules of Practice and Procedure in 10 CFR part 2. Interested persons should consult a current copy of 10 CFR 2.309. If a petition is filed, the Commission or a presiding officer will rule on the petition and, if appropriate, a notice of a hearing will be issued.
Petitions must be filed no later than 60 days from the date of publication of this notice in accordance with the filing instructions in section IV of this document. Petitions and motions for leave to file new or amended contentions that are filed after the deadline will not be entertained absent a determination by the presiding officer that the filing demonstrates good cause by satisfying the three factors in 10 CFR 2.309(c)(1)(i) through (iii).
A State, local governmental body, Federally recognized Indian Tribe, or designated agency thereof, may submit a petition to the Commission to participate as a party under 10 CFR 2.309(h) no later than 60 days from the date of publication of this notice. Alternatively, a State, local governmental body, Federally recognized Indian Tribe, or agency thereof may participate as a non-party under 10 CFR 2.315(c).
For information about filing a petition and about participation by a person not a party under 10 CFR 2.315, see ADAMS Accession No. ML20340A053 (https://adamswebsearch2.nrc.gov/webSearch2/main.jsp?AccessionNumber=ML20340A053) and on the NRC's public website at https://www.nrc.gov/about-nrc/regulatory/adjudicatory/hearing.html#participate.
IV.
All documents filed in NRC adjudicatory proceedings, including documents filed by an interested State, local governmental body, Federally recognized Indian Tribe, or designated agency thereof that requests to participate under 10 CFR 2.315(c), must be filed in accordance with 10 CFR 2.302. The E-Filing process requires participants to submit and serve all adjudicatory documents over the internet, or in some cases, to mail copies on electronic storage media, unless an exemption permitting an alternative filing method, as further discussed, is granted. Detailed guidance on electronic submissions is located in the Guidance for Electronic Submissions to the NRC (ADAMS Accession No. ML13031A056), and on the NRCs public website (https://www.nrc.gov/site-help/e-submittals.html).
To comply with the procedural requirements of E-Filing, at least 10 days prior to the filing deadline, the participant should contact the Office of the Secretary by email at Hearing.Docket@nrc.gov, or by telephone at 301-415-1677, to: (1) request a digital identification (ID) certificate which allows the participant (or its counsel or representative) to digitally sign submissions and access the E-Filing system for any proceeding in which it is participating; and (2) advise the Secretary that the participant will be submitting a petition or other adjudicatory document (even in instances in which the participant, or its counsel or representative, already holds an NRC-issued digital ID certificate). Based upon this information, the Secretary will establish an electronic docket for the proceeding if the Secretary has not already established an electronic docket.
Information about applying for a digital ID certificate is available on the NRC's public website at https://www.nrc.gov/site-help/e-submittals/getting-started.html. After a digital ID certificate is obtained and a docket is created, the participant must submit adjudicatory documents in the Portable Document Format. Guidance on submissions is available on the NRCs public website at https://www.nrc.gov/site-help/electronic-sub-ref-mat.html. A filing is considered complete at the time the document is submitted through the NRCs E-Filing system.
To be timely, an electronic filing must be submitted to the E-Filing system no later than 11:59 p.m. eastern time (ET) on the due date. Upon receipt of a transmission, the E-Filing system time-stamps the document and sends the submitter an email confirming receipt of the document. The E-Filing system also distributes an email that provides access to the document to the NRCs Office of the General Counsel and any others who have advised the Office of the Secretary that they wish to participate in the proceeding, so that the filer need not serve the document on those participants separately. Therefore, applicants and other participants (or their counsel or representative) must apply for and receive a digital ID certificate before adjudicatory documents are filed in order to obtain access to the documents via the E-Filing system.
A person filing electronically using the NRCs adjudicatory E-Filing system may seek assistance by contacting the NRC's Electronic Filing Help Desk through the Contact Us link located on the NRCs public website at https://www.nrc.gov/site-help/e-submittals.html, by email to MSHD.Resource@nrc.gov, or by a toll-free call at 1-866-672-7640. The NRC Electronic Filing Help Desk is available between 9 a.m. and 6 p.m., ET, Monday through Friday, except Federal holidays.
Participants who believe that they have good cause for not submitting documents electronically must file an exemption request, in accordance with 10 CFR 2.302(g), with their initial paper filing stating why there is good cause for not filing electronically and requesting authorization to continue to submit documents in paper format. Such filings must be submitted in accordance with 10 CFR 2.302(b)-(d). Participants filing adjudicatory documents in this manner are responsible for serving their documents on all other participants. Participants granted an exemption under 10 CFR 2.302(g)(2) must still meet the electronic formatting requirement in 10 CFR 2.302(g)(1), unless the participant also seeks and is granted an exemption from 10 CFR 2.302(g)(1).
Documents submitted in adjudicatory proceedings will appear in the NRCs electronic hearing docket, which is publicly available at https://adams.nrc.gov/ehd, unless otherwise excluded pursuant to an order of the presiding officer. If you do not have an NRC-issued digital ID certificate as previously described, click cancel when the link requests certificates and you will be automatically directed to the NRC's electronic hearing docket where you will be able to access any publicly available documents in a particular hearing docket. Participants are requested not to include personal privacy information such as social security numbers, home addresses, or personal phone numbers in their filings unless an NRC regulation or other law requires submission of such information. With respect to copyrighted works, except for limited excerpts that serve the purpose of the adjudicatory filings and would constitute a Fair Use application, participants should not include copyrighted materials in their submission.
The attorney for the permit holder is Christine Wu, Senior Counsel and Corporate Secretary, SHINE Technologies, LLC, 3400 Innovation Court, Janesville, WI 53546.
V.
Accordingly, pursuant to Section 161 of the Atomic Energy Act of 1954, as amended; 42 U.S.C. Section 2201; and 10 CFR 50.90 and 10 CFR 50.55(b), IT IS HEREBY ORDERED that CP No. CPMIF-001 is amended to extend the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029.
This order is effective upon issuance.
Dated: December 4, 2025.
FOR THE NUCLEAR REGULATORY COMMISSION.
Jonathan Greives, Director (Acting),
Division of Advanced Reactors and Non-Power Production and Utilization Facilities, Office of Nuclear Reactor Regulation.
JONATHAN GREIVES Digitally signed by JONATHAN GREIVES SHINE TECHNOLOGIES, LLC DOCKET NO. 50-608 SHINE MEDICAL ISOTOPE PRODUCTION FACILITY AMENDMENT TO CONSTRUCTION PERMIT Amendment No. 5 Construction Permit No. CPMIF-001 1.
The U.S. Nuclear Regulatory Commission (the Commission) has found that:
A. The application for an amendment to Construction Permit No. CPMIF-001, filed by SHINE Technologies, LLC (the licensee) on August 14, 2025, complies with the standards and requirements of the Atomic Energy Act of 1954, as amended (the Act),
and the Commissions rules and regulations set forth in Title 10 of the Code of Federal Regulations (10 CFR) Chapter I; B. The facility will be constructed in conformity with the application, the provisions of the Act, and the rules and regulations of the Commission; C. There is reasonable assurance that (i) the activities authorized by this amendment can be conducted without endangering the health and safety of the public, and (ii) such activities will be conducted in compliance with the Commissions regulations; D. The issuance of this amendment will not be inimical to the common defense and security or to the health and safety of the public; E. The issuance of this amendment is in accordance with 10 CFR Part 51, Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions, of the Commissions regulations and all applicable requirements have been satisfied; and F. Prior notice of this amendment was not required by 10 CFR 2.105, Notice of proposed action, and publication of a notice of issuance for this amendment is not required by 10 CFR 2.106, Notice of issuance.
2.
Accordingly, Construction Permit No. CPMIF-001 is amended as indicated in the attachment to this amendment.
3.
This amendment is effective as of its date of issuance and shall be implemented within 90 days.
FOR THE NUCLEAR REGULATORY COMMISSION Jeffrey S. Rady, Chief Non-Power Production and Utilization Facility Licensing Branch Division of Advanced Reactors and Non-Power Production and Utilization Facilities Office of Nuclear Reactor Regulation
Attachment:
Changes to Construction Permit No. CPMIF-001 Date of Issuance: December 4, 2025 JEFFREY RADY Digitally signed by JEFFREY RADY
Attachment ATTACHMENT TO AMENDMENT NO. 5 SHINE MEDICAL ISOTOPE PRODUCTION FACILITY CONSTRUCTION PERMIT NO. CPMIF-001 DOCKET NO. 50-608 Replace the following pages of Construction Permit No. CPMIF-001 with the attached revised pages. The revised pages are identified by amendment number and contain lines in the margin indicating the areas of change.
Construction Permit No. CPMIF-001 Remove Insert 1
1 2
2
1 Amendment No. 5 December 4, 2025 SHINE TECHNOLOGIES, LLC DOCKET NO. 50-608 MEDICAL ISOTOPE PRODUCTION FACILITY CONSTRUCTION PERMIT Amendment No. 5 Construction Permit No. CPMIF-001 1.
The Nuclear Regulatory Commission (NRC or the Commission) has found that:
A. The application for a construction permit, as supplemented and revised (the application),
filed by SHINE Medical Technologies, LLC1 (SHINE, the applicant), complies with the requirements of the Atomic Energy Act of 1954, as amended (the Act), and the rules and regulations of the Commission set forth in Title 10 of the Code of Federal Regulations (10 CFR) Chapter I - Nuclear Regulatory Commission. There is reasonable assurance that the activities authorized by the permit will be conducted in compliance with the rules and regulations of the Commission, and all required notifications to other agencies or bodies have been duly made; B. The applicant has described the proposed design of the facility, including, but not limited to, the principal architectural and engineering criteria for the design, and has identified the major features or components incorporated therein for the protection of the health and safety of the public; C. Such further technical or design information as may be required to complete the safety analysis, and which can reasonably be left for later consideration, will be supplied in the final safety analysis report; D. Safety features or components, if any, which require research and development have been described by the applicant. The applicant has identified, and will conduct, a research and development program reasonably designed to resolve any safety questions associated with such features or components; E. On the basis of the foregoing, there is reasonable assurance that: (i) such safety questions will be satisfactorily resolved at or before the latest date stated in the application for the completion of construction of the proposed facility, and (ii) taking into consideration the site criteria contained in 10 CFR Part 100,2 the proposed facility can be constructed and operated at the proposed location without undue risk to the health and safety of the public; 1
The permit holders name was administratively changed from SHINE Medical Technologies, LLC to SHINE Technologies, LLC as part of Amendment No. 3.
2 While the site criteria contained in 10 CFR Part 100 are applicable to nuclear power reactors, and not the SHINE facility, the staff considered in Chapter 2 of its safety evaluation report, site-specific conditions similar to those listed in 10 CFR Part 100. Using the guidance in NUREG-1537, the staff evaluated SHINEs analysis of site geography and demography; nearby industrial, transportation, and military facilities; site meteorology; site hydrology; and site geology, seismology, and geotechnical engineering to ensure that issuance of the permit will not be inimical to the common defense and security or to the health and safety of the public.
2 Amendment No. 5 December 4, 2025 F. The processes to be performed provide reasonable assurance the applicant will comply with the regulations in 10 CFR Chapter I, including the regulations in 10 CFR Part 20, and that the health and safety of the public will not be endangered.;
G. SHINE is technically qualified to design and construct the facility in accordance with the Commissions regulations set forth in 10 CFR Chapter I; H. SHINE is financially qualified to design and construct the facility in accordance with the Commissions regulations set forth in 10 CFR Chapter I; I.
The issuance of a permit for the construction of the facility will not be inimical to the common defense and security or to the health and safety of the public; and J.
After weighing the environmental, economic, technical and other benefits of the facility against environmental and other costs and considering reasonable available alternatives, the issuance of this construction permit, subject to the conditions for protection of the environment set forth herein, is in accordance with Subpart A of 10 CFR Part 51 of the Commissions regulations and all applicable requirements have been satisfied.
K. The receipt and possession of byproduct material, source material, and special nuclear material as authorized by this license will be in accordance with the Commissions regulations in 10 CFR Parts 30. 40, and 70.
2.
On the basis of the foregoing findings regarding this facility, construction permit No CPMIF-001 is hereby issued to SHINE pursuant to Sections 103 and 185a of the Act and 10 CFR Part 50 for eight utilization facilities and one production facility designed for the production of medical radioisotopes, as described in the application, filed in this matter by the applicant and as more fully described in the evidence received at the public hearing upon that application. The facility, known as the SHINE Medical Isotope Production Facility, owned by SHINE Technologies, LLC, will be located on previously undeveloped agricultural property in Rock County, Wisconsin, within the southern corporate boundaries of the City of Janesville, and is described in the application.
3.
This permit shall be deemed to contain and be subject to the conditions specified in 10 CFR 50.54(b)-(f), (h), (v), (aa), and (cc) and 10 CFR 50.55; is subject to all applicable provisions of the Act, and rules, regulations, and orders of the Commission now or hereafter in effect; and is subject to the conditions specified or incorporated below:
A. The earliest date for the completion of the construction of the facility is December 31, 2017, and the latest date for completion is December 31, 2029.
B. The facility shall be constructed and located at the site as described in the application, in the City of Janesville, Rock County, Wisconsin.
C. The construction permit authorizes the applicant to construct the facility described in the application and the hearing record, in accordance with the principal architectural and engineering criteria and environmental protection commitments set forth therein.
D. The permit is subject to, and SHINE shall comply with, the conditions specified and incorporated below:
SAFETY EVALUATION BY THE OFFICE OF NUCLEAR REACTOR REGULATION RELATED TO AMENDMENT NO. 5 TO CONSTRUCTION PERMIT NO. CPMIF-001 SHINE TECHNOLOGIES, LLC SHINE MEDICAL ISOTOPE PRODUCTION FACILITY DOCKET NO. 50-608
1.0 INTRODUCTION
By letter dated August 14, 2025 (Agencywide Documents Access and Management System Accession No. ML25226A150), SHINE Technologies, LLC (SHINE, the licensee) submitted to the U.S. Nuclear Regulatory Commission (NRC, the Commission) a license amendment request (LAR) for Construction Permit No. CPMIF-001 for the SHINE Medical Isotope Production Facility (SHINE facility) in accordance with Title 10 of the Code of Federal Regulations (10 CFR) 50.90, Application for amendment of license, construction permit, or early site permit, and 10 CFR 50.55(b). The proposed amendment would extend the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029, to allow the licensee to complete the construction of the facility.
2.0 REGULATORY EVALUATION
The NRC staff reviewed the LAR and evaluated the proposed change to Construction Permit No. CPMIF-001 based on the following regulations:
Section 50.55, Conditions of construction permits, early site permits, combined licenses, and manufacturing licenses, of 10 CFR, which provides, in part, the terms and conditions to which each construction permit is subject. These include 10 CFR 50.55(b), which states that if the proposed construction of a facility is not completed by the latest completion date, the construction permit will expire. However, the regulation further states that, upon good cause shown, the Commission will extend the completion date for a reasonable period of time.
Section 50.90, of 10 CFR, which states, in part, that whenever a holder of a construction permit desires to amend the permit, application for an amendment must be filed with the Commission fully describing the changes desired, and following as far as applicable, the form prescribed for original applications.
Section 50.92, Issuance of amendment, of 10 CFR, which states, in part, that in determining whether an amendment to a construction permit will be issued to the applicant, the Commission will be guided by the considerations which govern the issuance of initial construction permits to the extent applicable and appropriate.
3.0 TECHNICAL EVALUATION
SHINE has proposed to construct and operate the SHINE facility in Rock County, Wisconsin to produce molybdenum-99 (Mo-99) through the irradiation and processing of a uranyl sulfate solution. The SHINE facility would comprise an irradiation facility and a radioisotope production facility. The irradiation facility would consist of eight subcritical operating assemblies (or irradiation units), which would be licensed as a utilization facility, as defined in 10 CFR 50.2, Definitions. The radioisotope production facility would consist of hot cell structures, licensed collectively as a production facility, as defined in 10 CFR 50.2, and associated structures, systems, and components for the processing of irradiated material and extraction and purification of Mo-99. The irradiation facility and the radioisotope production facility are collectively referred to as the SHINE facility. The NRC issued Construction Permit No. CPMIF-001 on February 29, 2016, to authorize SHINE to construct the SHINE facility.
The SHINE facility is currently under construction at the site described in the construction permit, in Rock County, Wisconsin. License Condition 3.A of Construction Permit No. CPMIF-001 states, in part, that the latest date for the completion of the construction of the SHINE facility is December 31, 2025. In the LAR, SHINE proposes to extend this latest date for the completion of construction to December 31, 2029, to allow SHINE to complete the construction of the facility. The following is the NRC staffs evaluation of this proposal against the applicable NRC requirements.
The NRCs regulation at 10 CFR 50.55(b) states the following:
If the proposed construction or modification of the facility is not completed by the latest completion date, the construction permit shall expire and all rights are forfeited. However, upon good cause shown, the Commission will extend the completion date for a reasonable period of time. The Commission will recognize, among other things, developmental problems attributable to the experimental nature of the facility or fire, flood, explosion, strike, sabotage, domestic violence, enemy action, an act of the elements, and other acts beyond the control of the permit holder, as a basis for extending the completion date.
In LAR section 3, Regulatory Evaluation, SHINE describes that it completed a review of the construction schedule for the SHINE facility and determined that construction will not be completed by December 31, 2025, the latest date for completion of the construction of the SHINE facility prescribed by the construction permit. SHINE states that the delays in the construction of the SHINE facility are attributable to its first-of-a-kind nature. SHINE further states that developmental effort delays include efforts contributing to engineering detailed design progression, procurement of unique and one-of-a-kind components, construction of a first-of-a-kind facility, and progression of an operating license application that has no precedent.
Therefore, SHINE now expects the construction of the SHINE facility to be substantially completed in 2027, and the remaining uncompleted items of construction completed in 2029. To accommodate this construction schedule and to incorporate conservatism, SHINE requests to extend the latest date for completion of the construction of the SHINE facility to December 31, 2029. SHINE does not request or propose any modification to the terms of the construction permit other than to extend the latest date for completion of construction. SHINE also states that this change would not authorize any new activities and would not have any radiological consequences.
Based on the information in the LAR, the NRC staff finds that, in accordance with 10 CFR 50.55(b) and 10 CFR 50.90, SHINE has shown good cause for amending Construction Permit No. CPMIF-001 to extend the latest date for completion of construction to December 31, 2029, and that this is a reasonable period of time. The staffs finding is based on the consideration that (1) the proposed new date is based on a detailed review and appropriately includes conservatism, (2) the reasons for the delay include developmental problems attributable to the first-of-a-kind nature of the SHINE facility and circumstances beyond SHINEs control, and (3) the proposed amendment to the construction permit only reflects this extension, does not propose any modifications to any other terms of the construction permit or authorize any new activities, and does not have any radiological consequences. Therefore, consistent with 10 CFR 50.55(b) and 10 CFR 50.92, the staff concludes that the requested amendment to Construction Permit No. CPMIF-001 to extend the latest date for completion of the construction of the SHINE facility from December 31, 2025, to December 31, 2029, is acceptable.
4.0 STATE CONSULTATION
In accordance with the Commissions regulations, the Wisconsin State official was notified on November 17, 2025, of the proposed issuance of the amendment (ML25324A141). The State official had no comments.
5.0 ENVIRONMENTAL CONSIDERATION
Pursuant to 10 CFR 51.21, Criteria for and identification of licensing and regulatory actions requiring environmental assessments, 10 CFR 51.32, Finding of no significant impact, and 10 CFR 51.35, Requirement to publish finding of no significant impact; limitation on Commission action, an environmental assessment and finding of no significant impact regarding the LAR was published in the Federal Register (FR) on November 28, 2025 (90 FR 54766). Accordingly, based upon the environmental assessment, the Commission has determined that the issuance of the amendment will not have a significant effect on the quality of the human environment.
6.0 CONCLUSION
The Commission has concluded, based on the considerations discussed above, that (1) there is reasonable assurance that the health and safety of the public will not be endangered by construction in the proposed manner, (2) there is reasonable assurance that such activities will be conducted in compliance with the Commissions regulations, and (3) the issuance of the amendment will not be inimical to the common defense and security or to the health and safety of the public.
Principal Contributor: M. Balazik, NRR Date: December 4, 2025